Quick Answer
ANI PHARMACEUTICALS INC reported Cash and Equivalents of $285.58 million for fiscal year 2025.
ANI PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $285.58M | +97.1% |
| 2024 | $144.86M | -34.5% |
| 2023 | $221.12M | +358.5% |
| 2022 | $48.23M | -51.9% |
| 2021 | $100.30M | +1175.4% |
| 2020 | $7.86M | -87.4% |
| 2019 | $62.33M | +44.9% |
| 2018 | $43.01M | +38.1% |
| 2017 | $31.14M | +13.8% |
| 2016 | $27.36M | -82.3% |
| 2015 | $154.68M | -8.5% |
| 2014 | $169.04M | +1422.2% |
| 2013 | $11.11M | +100854.5% |
| 2012 | $11.0K | — |
| 2011 | $0.00 | -100.0% |
| 2010 | $38.16M | +27.8% |
| 2009 | $29.86M | +153.9% |
| 2008 | $11.76M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $262.61M | +81.1% | +20.6% |
| June 30, 2025 | $217.80M | -9.3% | +45.4% |
| March 31, 2025 | $149.80M | -34.5% | +3.4% |
| December 31, 2024 | $144.86M | -34.5% | -0.1% |
| September 30, 2024 | $144.98M | -24.9% | -39.6% |
| June 30, 2024 | $240.11M | +48.5% | +5.0% |
| March 31, 2024 | $228.60M | +237.4% | +3.4% |
| December 31, 2023 | $221.12M | +358.5% | +14.5% |
- ANI PHARMACEUTICALS INC showed an increase of +97.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, ANI PHARMACEUTICALS INC’s cash and equivalents has grown by 2328.3% (from $11.76 million to $285.58 million).
- The most recent figure is from ANI PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: